Platelet-Expressed Synaptophysin (Psyn) As Novel Biomarker In Neuroendocrine Malignancies

Simple SummaryThis study describes the expression of synaptophysin on platelet surfaces of neuroendocrine neoplasms (NENs). Compared to healthy donors, platelet-expressed synaptophysin was shown to be significantly upregulated in NENs patients. Platelet-expressed synaptophysin was significantly correlated with tumor proliferation and metastasis, demonstrating the involvement of platelets in tumor biology. Expression of synaptophysin on platelet surfaces was finally shown to predict progression-free survival in NEN. This study conceptually explored platelet-expressed synaptophysin as a novel biomarker in NEN.Neuroendocrine neoplasms (NENs) encompass a heterogeneous group of tumors. Whereas low-grade neuroendocrine tumors (NETs) are histologically well-differentiated, highly aggressive neuroendocrine carcinomas (NECs) are characterized by a high proliferation rate and a worse clinical outcome. Since most NEN patients need monitoring of tumor progress and response to treatment for a long period of time, especially in metastatic disease, reliable, dynamic, and easy-to-assess biomarkers are needed. In this prospective study, we identified platelet-expressed synaptophysin (pSyn) as a novel biomarker in NENs. The level of pSyn in NENs was significantly upregulated compared to healthy donors. pSyn was positively correlated with higher tumor stages, the occurrence of metastasis, histological grading, and higher tumor proliferation (Ki67). Most importantly, high pSyn expression in our NEN cohort was shown to predict shorter progression-free survival (PFS). In conclusion, our data highlight the potential of pSyn as a novel biomarker in NENs reflecting tumor stages, grading, and prognosis.